Rovi stock sits 32.47 percent below its EUR 86.70 high

Published on 10/12/2026 at 10:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi stock stands 32.47 percent below its EUR 86.70 high. It costs EUR 58.55 on October 12, 2026 in trading at Lang & Schwarz.

Key points in brief

Rovi stock stood at EUR 58.55 at Lang & Schwarz on October 12, 2026, 32.47 percent below its EUR 86.70 52-week high.
Rovi reported EUR 357.0 million of total revenue in the first half of 2026, up 13.00 percent year over year.
The company will publish first nine months 2026 results on November 5, 2026.
Jefferies cut its Rovi price target from EUR 83.50 to EUR 64.20 while retaining a Hold rating in its May 13, 2026 note.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi (ES0157261019) was trading at EUR 58.55 at Lang & Schwarz on October 12, 2026 at 10:01 a.m. CEST, 32.47 percent below its EUR 86.70 52-week high. The company has scheduled its first nine months 2026 financial results for November 5, 2026, according to Rovi.

Three dates explain the setup

On April 1, 2026, Rovi completed the acquisition of an injectable manufacturing facility in Phoenix, Arizona, and recognized a EUR 62.40 million bargain purchase gain in the first half of 2026, as described in the Yahoo Finance transcript.

On May 13, 2026, Jefferies cut its price target from EUR 83.50 to EUR 64.20 and retained a Hold rating, according to Bolsamania. On July 23, 2026, Rovi reported first-half revenue of EUR 357.00 million, up 13.00 percent from the first half of 2025, according to Yahoo Finance.

What does the revenue mix show?

The first-half operating revenue reached EUR 344.20 million, a 9.00 percent year-over-year increase, while contract manufacturing revenue rose 38.00 percent to EUR 106.30 million. That mix matters because the CDMO business is becoming a larger operating driver as Rovi integrates the Phoenix facility.

Gross profit increased 21.00 percent to EUR 237.10 million in the first half of 2026, while gross margin reached 68.90 percent, an improvement of 6.50 percentage points. The transcript identifies R&D grant income related to the LAISOLID project as one contributor, so the reported margin also includes a specific one-off-related factor.

Dates and valuation remain central

Rovi's investor calendar lists November 5, 2026 for first nine months 2026 financial results. The upcoming report will give investors a fresh checkpoint on CDMO growth, heparin demand and the contribution from the Phoenix operation.

At EUR 58.55, Rovi's market capitalization was EUR 3.0 billion on October 12, 2026, while its reported 52-week range was EUR 53.10 to EUR 86.70 as of October 9, 2026. The stock therefore sits materially closer to its yearly low than its yearly high, while the latest reported revenue comparison points to double-digit group growth.

Rovi stock stays below its yearly high

Rovi was trading at EUR 58.55 at Lang & Schwarz on October 12, 2026 at 10:01 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Rovi stock.